Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Emergent BioSolutions’ valuation looks rather restrained than convincingly cheap: on the multiples, the company trades noticeably below the industry median, but this largely reflects weak profitability and unstable earnings. P/S of 0.69, P/B of 0.99, and P/FCF of 4.56 look inexpensive relative to the sector, but P/E and ROE/ROA/ROI on a TTM basis do not really provide qualitative confirmation of this cheapness, since profitability in the current period has almost disappeared. Historically, margins were better: operating margin last year reached 13–15%, but now has fallen to 9.16%, indicating deteriorating operating leverage. Gross margin remains acceptable at 55.84%, but it is still below the industry median, so the company’s pricing power does not look outstanding. Revenue in TTM rose to $234 million, supporting the picture of business scale, but growth alone does not offset the weak conversion of sales into net profit. Net income and operating income in the current period are positive, but very small relative to revenue, and net profit margin in TTM is zero, signaling instability in bottom-line profitability. The liquidity position is strong: current ratio of 5.42 and quick ratio of 2.95 are well above the industry, so short-term obligations are covered comfortably. At the same time, leverage remains significant: debt/equity of 1.10 is above the median, and long-term debt of $582 million versus equity of $341 million limits financial flexibility. The decline in cash on hand from $271 million to $141 million over the year also looks like a cautionary factor, especially amid shrinking capital and assets. Equity and assets have been declining over recent periods, which does not add confidence in the balance sheet’s sustainability. The company does not pay dividends, so shareholders do not receive compensation for elevated risk through yield. Overall, the fundamentals send a mixed signal: the stock looks inexpensive on multiples, but earnings quality, margin stability, and capital dynamics are not yet strong enough to justify aggressively raising the target valuation. For an investor, this is more a story of cautious waiting for operating improvement than of confident re-rating growth.

Emergent BioSolutions Inc.

Сильный индекс, значительно упал. Быки в растерянности.

Strong index, significantly down. The bulls are confused.

Сильный индекс, незначительно вырос. Рынок на стороне быков.

Strong index, slightly up. The market is on the bulls' side.

Слабый индекс, незначительно вырос. Приток средств в лонги остается на невысоком уровне.

Weak index, slightly up. The inflow of funds into longs remains at a low level.

The shares look inexpensive on valuation multiples, but weak and unstable profitability, high debt, and declining equity limit re-rating potential.

(RTTNews) - Emergent BioSolutions Inc. (EBS) announced it has received a contract modification valued at approximately $24 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services.
The award supports continued supply of CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted) for national anthrax preparedness efforts.
Anthrax remains a significant biological threat due to its potential use in bioterrorism and its impact on public health and national security. CYFENDUS, approved by the FDA in July 2023, is indicated for post-exposure prophylaxis in adults aged 18 through 65 when administered with antibacterial drugs.
Emergent emphasized that the modification underscores the government's commitment to maintaining readiness against anthrax threats. Paul Williams, senior vice president at Emergent, noted the company's focus on ensuring access to CYFENDUS and strengthening preparedness through reliable domestic manufacturing and supply.
This award builds on Emergent's longstanding partnership with the U.S. government, including earlier contracts for BioThrax, another anthrax vaccine.
EBS has traded between $4.36 and $14.06 over the past year. The stock is currently trading at $6.15, up 0.82%.

Emergent BioSolutions Secures $24M Contract Modification For CYFENDUS Anthrax Vaccine

(RTTNews) - This week's biotech roundup captured a mix of regulatory wins, restructuring action, and deal momentum driving sector sentiment. FDA and EU approvals spanned oncology, vaccines and rare disease, while layoffs and cost-saving measures underscored operational tightening across the sector. Strategic acquisitions and licensing agreements advanced pipeline diversification, and clinical trial updates delivered both progress and setbacks in Parkinson's, obesity, and endometrial cancer, reflecting the industry's dynamic balance between innovation and volatility.
Read on...
FDA and EC Approvals
Replimune Group, Inc. (REPL) secured FDA approval for its oncolytic immunotherapy TUDRIQEV (vusolimogene oderparepvec-wtpg) in advanced cutaneous melanoma, in combination with Bristol Myers Squibb's Nivolumab for patients progressing after anti-PD-1 therapy.
The IGNYTE trial supported the decision, showing a 24.2% response rate and median duration of 14.1 months.
REPL closed Thursday's trading (August 6, 2026) at $12.86, up 8.71%.
Takeda (TAK) won FDA approval for ORZEYFUL (oveporexton), the first orexin receptor 2 agonist, for narcolepsy type 1 in adults. The therapy directly targets orexin deficiency, addressing the root cause rather than symptoms, with Phase 3 FirstLight (TAK-861-3001) and RadiantLight (TAK-861-3002) studies demonstrating significant improvements in sleepiness and cataplexy.
TAK closed Thursday's trading at $17.02, up 1.79%.
Moderna, Inc. (MRNA) secured FDA approval for mFLUSIVA (mRNA-1010), the first mRNA-based flu vaccine for adults aged 50 and older. The decision, backed by unanimous VRBPAC support, was based on Phase 3 data from over 40,000 participants.
The use of this vaccine in adults aged 65 and older was granted accelerated approval based on immunogenicity results from a separate Phase 3 study. Supply is expected in select U.S. retailers within weeks, marking Moderna's fifth global approval.
MRNA closed Thursday's trading at $53.86, down 4.26%.
Sanofi (SNY) received European Commission approval expanding MenQuadfi use to infants from six weeks of age for protection against invasive Meningococcal disease (serogroups A, C, W, and Y). The decision followed by CHMP's positive opinion and was supported by the MET58 study showing safety and immunogenicity in infants.
SNY closed Thursday's trading at $42.89, up 0.26%.
Novartis (NVS) received FDA approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor for PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC).
The Phase III PSMAddition trial showed the combo reduced risk of progression or death by 28%, with updated analysis showing a 33% reduction and positive survival trend. The approval nearly doubles the eligible patient population, making Pluvicto the only PSMA-targeted therapy cleared across all stages of metastatic prostate cancer.
NVS closed Thursday's trading at $154.21, down 0.15%.
Layoffs
Lisata Therapeutics, Inc. (LSTA) slashed 72% of its workforce, including the EVP of R&D and CMO roles, as part of a cash-preservation drive during a strategic review following its terminated merger with Kuva Acquisition Corp. Some staff may continue temporarily as consultants.
LSTA closed Thursday's trading at $1.07, down 4.46%
Emergent BioSolutions (EBS) reported a sharp 66% jump is Q2 revenue to $234.3 million, driven by U.S. government contract modifications. However, a $191 million non-cash impairment widened its net loss to $180 million. The company announced a restructuring plan cutting 93 roles and closing Gaithersburg labs to save $40 million annually.
EBS closed Thursday's trading at $5.31, down 29.58%
Deals
Tarsus Pharmaceuticals, Inc (TARS), a biopharmaceutical company focused on eye care, has entered into a definitive agreement to acquire Alkeus Pharmaceuticals, Inc., a retinal disease-focused biotechnology company, for up to $800 million.
The pending transaction involves $450 million in upfront consideration consisting of $270 million in cash and $180 million in Tarsus common stock priced at $61.38 per share, plus up to $350 million in milestone payments.
The acquisition includes Alkeus' lead candidate Gildeuretinol (ALK-001) in Phase 3 development for Stargardt disease, a rare inherited retinal disorder with no FDA-approved treatment. The acquisition is expected to close in 2026, subject to customary conditions.
TARS closed Thursday's trade at $65.33, up 6.69%.
Evotec SE (EVO) has entered into a strategic research and development collaboration with Odyssey Therapeutics, Inc. (ODTX) to accelerate discovery of new treatments for autoimmune and inflammatory diseases harnessing AI. Under the agreement, Odyssey will leverage Evotec's AI-enabled discovery platform, advanced screening capabilities, and proprietary compound libraries to identify and validate differentiated small-molecule drug candidates across multiple high value disease targets.
EVO closed Thursday's trade at $1.95, down 1.52%. ODTX closed Thursday's trade at $21.55, up 3.16%.
Eton Pharmaceuticals, Inc. (ETON) licensed the U.S. rights to ASN-001, a topical timolol gel, from Shanghai Auson Pharmaceuticals, for the treatment of proliferating superficial infantile hemangiomas, a benign vascular tumour. Eton will run a bioavailability bridging study for ASN-001 and intends to submit the New Drug Application (NDA) upon completion of the study in the second half of 2027.
ETON closed Thursday's trade at $46.18, up 0.46%.
KKR, an investment firm, has signed definitive agreements to acquire Medicover India, the hospital operations of Medicover AB (MCOV-B.ST), which specifically operates a multi-specialty hospital network comprising 24 hospitals and approximately 4,800 beds across South and West India. The financial details remain undisclosed.
MCOV-B.ST closed Thursday's trade at SEK242.50, down 0.41%
SRX Global Inc. (SRXH) has acquired a stake in Vistagen Therapeutics, Inc. (VTGN), a late clinical-stage biopharmaceutical company focused on neuroscience. SRX said it views Vistagen shares as undervalued and intends to engage with management and the board.
SRXH closed Thursday's trade at $1.43, up 2.88%. VTGN closed Thursday's trade at $0.28, down 4.44%.
Profusa Inc. (PFSA), a digital health company, announced the signing of an option agreement that provides Profusa the right and option to acquire G3 Vision Labs, Inc., which provides testing solutions, clinical insight, and reporting tools for health care teams.
As consideration for the option, Profusa issued 201,120 common shares and 52,903.566 shares of Series A non-voting convertible preferred stock. If Profusa exercises the option, the counterparties will be entitled to receive an additional 53,918.113 preferred shares. Profusa's ability to exercise the option is subject to stockholder approval.
PFSA closed Thursday's trade at $0.93, down 0.20%.
Clearmind Medicine Inc. (CMND) announced that it has entered into a non-binding Letter of Intent to acquire a 51% stake in an intelligent EV (electric vehicles) wireless charging solutions company for automated parking systems and autonomous mobile platforms for an aggregate purchase price of $2.5 million.
Meanwhile, the announcement did not explain the operational or technical relevance of the proposed acquisition to Clearmind Medicine's drug development business.
CMND closed Thursday's trade at $1.75, down 0.57%.
Clinical Trials - Breakthroughs & Setbacks
BioVie Inc. (BIVI) announced that its investigational candidate Bezisterim met its primary endpoint in the Phase 2 SUNRISE-PD trial in early-stage Parkinson's disease, showing statistically significant improvements across motor and non-motor symptoms along with beneficial impact on plasma biomarkers of neurodegeneration and reduced biomarkers of both neuro and systemic inflammation.
In addition, with a well-tolerated safety profile, participants receiving Bezisterim experienced greater improvements than placebo across daily living, motor, and non-motor outcomes, meeting prespecified endpoints and achieving proof of concept, according to the company. With the findings so far, BioVie plans to advance Bezisterim into pivotal Phase 3 development.
BIVI closed Thursday's trade at $1.35, down 33.82%.
Rhythm Pharmaceuticals, Inc. (RYTM) announced preliminary results from its ongoing Phase 2 trial of RM-718, an investigational once-weekly MC4R agonist, in patients with acquired hypothalamic obesity showing an 11.6% reduction in mean BMI from baseline after 16 weeks of RM-718.
According to the company, RM-718 was generally well tolerated, with efficacy results at 16 weeks comparable to a mean BMI reduction of 10.1% with bivamelagon 600 mg dose at 14 weeks and a 10.1% BMI reduction with setmelanotide at 16 weeks.
RYTM closed Thursday's trade at $112.10, up 1.26%.
Karyopharm Therapeutics Inc. (KPTI) announced that Selinexor did not meet the primary progression-free survival goal in the Phase 3 XPORT-EC-042 trial evaluating it as a maintenance-only therapy in patients with TP53 wild-type advanced or recurrent endometrial cancer. Meanwhile, the company said a favourable trend was observed in the Selinexor arm.
Karyopharm plans to continue following patients for longer-term outcomes and present full data.
KPTI closed Thursday's trade at $1.95, up 2.09%.
For more biotechstock news visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

(RTTNews) - Emergent BioSolutions Inc. (EBS), a life sciences company focused on public health preparedness and medical countermeasures, reported financial results for the second quarter ended June 30, 2026.
Total revenue for Q2 2026 rose sharply to $234.3 million, up 66% from $140.9 million in Q2 2025, primarily driven by accelerated modifications to U.S. government contracts under its medical countermeasures (MCM) and biodefense portfolio.
The company recorded a net loss of $180.2 million, compared to a net loss of $12.0 million in Q2 2025, largely due to a $191.3 million non-cash impairment charge related to its Naloxone business.
Adjusted net income improved to $30.9 million, up 134% from $13.2 million a year earlier.
Adjusted EBITDA rose to $96.5 million, a 192% increase from $33.1 million in Q2 2025, reflecting stronger operational performance.
Gross margin expanded to 50%, compared to 36% in the prior-year quarter, while adjusted gross margin reached 58%, up from 49%.
Adjusted EBITDA margin improved to 41%, versus 23% in Q2 2025, underscoring efficiency gains across manufacturing and contract operations.
CEO Joe Papa stated that the quarter "significantly exceeded the high end of our guidance," citing disciplined execution and renewed focus on transformation. He noted that the company is aligning resources to the realities of the naloxone business while preserving the ability to invest in areas that matter most for Emergent's future."
2026 Financial Forecast
Emergent reduced its full-year 2026 guidance compared with prior expectations issued in April.
-Total revenues are now projected at $645- $675 million, down from the previous forecast of $720-$760 million, compared with $742.9 million in FY2025.
-Net loss is expected at $(245)- $(225) million, widened from the earlier range of $(30)-$(10) million, versus net income of $52.6 million in FY 2025.
-Adjusted net income is forecast at $10-$30 million, cut from $45-$65 million, compared with $86.8 million in FY 2025.
-Adjusted EBITDA is expected at $130-$150 million, reduced from $155-$175 million, compared with $205.0 million in FY 2025.
-Adjusted gross margin is projected at 42-44%, lower than the prior 45-47%, compared with 54% in FY 2025.
- And for Q3 2026 the company is expecting revenue to be in the range of $110- $130 million, compared to $231.1 million in Q2 2025.
Restructuring Update (Form 8-K Filing, August 5, 2026):
Emergent announced an organizational restructuring plan aimed at strengthening its long-term financial position. The plan includes a reduction of approximately 93 employees, elimination of 21 vacant positions, and the closure of wet laboratories in Gaithersburg, Maryland.
These actions are expected to generate annualized savings of about $40 million once fully implemented. The company anticipates $10- $11.5 million in restructuring charges, primarily related to severance, transition services, and benefits, to be incurred in the second half of 2026.
EBS has traded between $5.06 and $14.06 over the past year. The stock closed Thursday's trading at $5.31, down 29.58%. In pre-market trading the stock is at $5.41, up 2.71%.
Shares hit a new 52-week low of $5.06 in yesterday's trading session.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Emergent BioSolutions Q2 Revenue Jumps, Net Loss Widens Amid Restructuring

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.
In trading on Thursday, shares of Emergent BioSolutions Inc (Symbol: EBS) entered into oversold territory, hitting an RSI reading of 20.6, after changing hands as low as $5.06 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 63.5. A bullish investor could look at EBS's 20.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of EBS shares:
Looking at the chart above, EBS's low point in its 52 week range is $5.06 per share, with $14.06 as the 52 week high point — that compares with a last trade of $5.31.
Further EBS Research:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Emergent BioSolutions is Now Oversold (EBS)

Data is currently not available
Edit My Quotes
Add up to 25 symbols
To add symbols:
Type a symbol or company name. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return.
Copy and paste multiple symbols separated by spaces.
These symbols will be available throughout the site during your session.
Save data
Data is currently not available
Edit My European Quotes
Add up to 25 instruments
To add instruments:
Type a instrument or company name. When the instrument you want to add appears, add it to My European Quotes by selecting it and pressing Enter/Return.
Copy and paste multiple instruments separated by spaces.
These instruments will be available throughout the site during your session.
Save data
Data is currently not available
Your symbols have been updated
You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com.
Continue
Data is currently not available
Edit Watchlist
Add up to 20 symbols
To add symbols:
Type a symbol or company name. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return.
Copy and paste multiple symbols separated by spaces.
These symbols will be available throughout the site during your session.
Save data

Emergent (EBS) Q4 2025 Earnings Transcript

(RTTNews) - Emergent BioSolutions (EBS) announced that the FDA has approved its supplemental New Drug Application for over-the-counter NARCAN Nasal Spray to be packaged in a new carrying case, which includes two blister packs. The company said the NARCAN carrying case will be made available soon to purchase for consumers nationwide at select retailers and online, as well as public interest customers through NARCANDirect, Emergent's ordering and distribution platform.
The company noted that, since the prescription launch of NARCAN Nasal Spray in 2016, more than 85 million doses have been distributed across the U.S. and Canada.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Emergent BioSolutions: FDA Approves SNDA For NARCAN Carrying Case

In trading on Monday, auto dealerships shares were relative laggards, down on the day by about 2.2%. Helping drag down the group were shares of America's Car-Mart, off about 4.3% and shares of AutoZone, down about 3.9% on the day.
Also lagging the market Monday are biotechnology shares, down on the day by about 2.1% as a group, led down by Emergent BioSolutions, trading lower by about 15.4% and Silence Therapeutics, trading lower by about 8.1%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Monday Sector Laggards: Auto Dealerships, Biotechnology Stocks

Data is currently not available
Edit My Quotes
Add up to 25 symbols
To add symbols:
Type a symbol or company name. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return.
Copy and paste multiple symbols separated by spaces.
These symbols will be available throughout the site during your session.
Data is currently not available
Edit My European Quotes
Add up to 25 instruments
To add instruments:
Type a instrument or company name. When the instrument you want to add appears, add it to My European Quotes by selecting it and pressing Enter/Return.
Copy and paste multiple instruments separated by spaces.
These instruments will be available throughout the site during your session.
Data is currently not available
Your symbols have been updated
You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com.
Data is currently not available
Edit Watchlist
Add up to 20 symbols
To add symbols:
Type a symbol or company name. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return.
Copy and paste multiple symbols separated by spaces.
These symbols will be available throughout the site during your session.
Data is currently not available
Opt in to Smart Portfolio
We are currently experiencing technical difficulties, please try again.
Smart Portfolio is supported by our partner TipRanks. By connecting my portfolio to TipRanks Smart Portfolio I agree to their Terms of Use.

Emergent BioSolutions (EBS) Earnings Transcript

Emergent BioSolutions (EBS) Q4 2024 Earnings Call Transcript

(RTTNews) - Below are the earnings highlights for Emergent BioSolutions Inc (EBS):
Earnings: -$31.3 million in Q4 vs. -$49.5 million in the same period last year. EPS: -$0.58 in Q4 vs. -$0.95 in the same period last year. Excluding items, Emergent BioSolutions Inc reported adjusted earnings of $2.6 million or $0.05 per share for the period.
Revenue: $194.7 million in Q4 vs. $276.6 million in the same period last year.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Periodand min./max. price, $	Price change, %		Volatility, %		Volume, $
Periodand min./max. price, $	EBS	Industry	EBS	Industry	Volume, $
Yesterday 6.1 - 6.8	-11.33	2.30	7.02	1.62	92.42K
Week 6.0 - 6.8	-6.12	9.25	4.67	2.73	30.78M
Month 6.0 - 7.6	-12.38	9.32	41.77	6.74	179.14M
3 Months 4.4 - 7.7	-19.42	8.16	49.51	13.68	430.53M
6 Months 4.4 - 9.7	-26.98	15.81	60.36	22.17	752.55M
Year 4.4 - 14.1	-39.03	8.16	78.13	38.79	1.66B
3 years 1.4 - 15.1	172.55	26.96	203.41	71.93	6.70B
5 years 1.4 - 52.8	-87.74	46.40	231.54	96.18	12.57B
All time 1.4 - 137.6	-27.87	75.35	—	—	23.26B

Emergent BioSolutions Inc.

Price and volatility history

Risk ratios